ArticleAnnals of translational medicine2017
Semaglutide seems to be more effective the other GLP-1Ras.
Article in Annals of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes.Acta pharmaceutica Sinica. B · 2026Review
- Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Anti-inflammatory benefits of semaglutide: State of the art.Journal of clinical & translational endocrinology · 2024Review
- Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss.American journal of physiology. Endocrinology and metabolism · 2024Review
- Evaluating the Clinical Effectiveness and Safety of Semaglutide in Individuals with Uncontrolled Type 2 Diabetes. Real-World Evidence from Saudi Arabia: The Observational, Multicenter, 15-Month EVOLUTION Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Effects of Semaglutide in Doxorubicin-Induced Cardiac Toxicity in Wistar Albino Rats.Cancer management and research · 2024Article
- Finding balance: understanding the energetics of time-restricted feeding in mice.Obesity (Silver Spring, Md.) · 2023Review
- Usage of Glucagon-Like Peptide-1 for Obesity in Children; Updated Review of Clinicaltrials.gov.Journal of multidisciplinary healthcare · 2023Review
- Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.Pharmaceutical research · 2022Review
- Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.Advances in therapy · 2022Article
- Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Article
- Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications.Bioengineered · 2022Article
- Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review.Clinical pharmacology : advances and applications · 2022Review
- Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing.Nature reviews. Drug discovery · 2020Review
- Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities.Drugs · 2019Review
- Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?World journal of hepatology · 2018Article
- Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients.Pharmacy (Basel, Switzerland) · 2018Review
- Battle of GLP-1 delivery technologies.Advanced drug delivery reviews · 2018Review
- Erratum to semaglutide seems to be more effective the other GLP-1Ras.Annals of translational medicine · 2018Article
Corrections and comments
- Comment on
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.